SCHEMBL16156111

SCHEMBL16156111

COCCOc1cc2ncnc(Nc3ccc4c(c3)CCN4)c2cc1OCCOC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.60
▸ EGFR P00533 14/20 0.59
▸ KDR P35968 4/20 0.59
▸ ILK Q13418 2/20 0.58
▸ GAK O14976 2/20 0.57
▸ FLT1 P17948 2/20 0.56
▸ ERBB2 P04626 2/20 0.56
▸ FGFR1 P11362 1/20 0.56
▸ FBP1 P09467 1/20 0.56
▸ PLK4 O00444 1/20 0.56
▸ CIT O14578 1/20 0.56
▸ AURKA O14965 1/20 0.56
▸ EPHB6 O15197 1/20 0.56
▸ SLC22A1 O15245 1/20 0.56
▸ DAPK3 O43293 1/20 0.56
▸ RIPK2 O43353 1/20 0.56
▸ BUB1 O43683 1/20 0.56
▸ JAK2 O60674 1/20 0.56
▸ RPS6KA4 O75676 1/20 0.56
▸ STK17B O94768 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16150108 0.89 EGFR (0.69) EGFRKDRGAKFLT1RIPK2
Hydrochloric Acid SCHEMBL16150696 0.88 EGFR (0.69) EGFRKDRGAKFLT1RIPK2
SCHEMBL19035526 0.84 EGFR (0.62) EGFRKDRGAKFLT1ERBB2
SCHEMBL2659830 0.83 KDR (0.61) EGFRKDRGAKFLT1FGFR1
SCHEMBL16156109 0.82 SRC (0.72) EGFRKDRGAKERBB2CIT
SCHEMBL18447218 0.78 KDM1A (0.77) KDM1AEGFRKDRILKGAK
SCHEMBL16660323 0.77 EGFR (0.77) KDM1AEGFRKDRILKGAK
SCHEMBL7708517 0.77 EGFR (0.77) KDM1AEGFRKDRILKGAK
SCHEMBL28105746 0.77 KDR (0.75) KDM1AEGFRKDRILKGAK
SCHEMBL20805304 0.77 EGFR (0.77) KDM1AEGFRKDRILKGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688662-B2 N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-06-27 — — US disclosed
EP-2989091-B1 NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-05-10 — — EP disclosed
WO-2014161808-A1 NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-09 — — WO disclosed
Send feedback